Skip to main content

Table 1 Clinical and laboratory parameters of patients diagnosed as having AIDS-associated cryptococcal meningitis between January 1999-March 2001 and from April 2001-December 2002 (before and during the fluconazole donation programme respectively)

From: Outcome of AIDS-associated cryptococcal meningitis initially treated with 200 mg/day or 400 mg/day of fluconazole

  Before April 2001 (n = 77) From April 2001 (n = 128) P value
Median age in years (range) 33 (17–75) 35 (21–66) 0.4
Male sex 36 (47%) 63 (49%) 0.7
Prior AIDS-defining illness 20 (26%) 26 (20%) 0.3
Prior tuberculosis 51 (66%) 91 (71%) 0.5
Concurrent TB treatment 33 (43%) 52 (41%) 0.8
CSF India Ink (n = 68) (n = 121) 0.2
   Positive 56 (82%) 88 (73%) 0.2
CSF CLAT titer (n = 50) (n = 82) 0.9
   ≥ 1000 36 (72%) 57 (70%) 0.9
   < 1000 14 (28%) 25 (30%)  
CSF fungal culture (n = 29) (n = 66) 0.07
   Positive 27 (93%) 51 (77%) 0.1
Level of consciousness    
   Stage 1 45 (58%) 70 (55%) 0.9
   Stage 2 30 (39%) 54 (42%)  
   Stage 3 2 (3%) 4 (3%)  
Therapeutic lumbar punctures (n = 7) (n = 23) 0.12
   Single 4 14 1.0
   Multiple 3 9  
Any treatment received    
   Yes 62 (81%) 121 (95%) <0.01
   No 15 (19%) 7 (5%)  
Type of initial treatment received (n = 62) (n = 121)  
   Fluconazole 200 45 (73%) 12 (10%) <0.001
   Fluconazole 400 4 (6%) 109 (90%)  
   Amphotericin B* 13 (21%) 0 (0%)  
  1. *This was only available at the local tertiary referral hospital. Following the donation referrals for amphotericin B were no longer accepted.